Evaluating the Clinical Effectiveness of 90Y-SMT 487 in Patients with Neuroendocrine Tumors
David Bushnell, MD1,2,
Thomas ODorisio, MD3,
Yusuf Menda2,
Thomas Carlisle, MD1,4,
Pamela Zehr, BA4,
Mary Connolly, PhD5,
Mark Karwal, MD4,
Sara Miller, BS1,
Stan Parker, MD1 and
Hakim Bouterfa, PhD5
1 Iowa City Veterans Administration Hospital, Diagnostic Imaging and Radioisotope Therapy Service, Iowa City, Iowa
2 Department of Radiology, Division of Nuclear Medicine, University of Iowa Roy J. and Lucille A. Carver College of Medicine, Iowa City, Iowa
3 Department of Internal Medicine, Division of Endocrinology, University of Iowa Roy J. and Lucille A. Carver College of Medicine, Iowa City, Iowa
4 Department of Internal Medicine, Division of Oncology, University of Iowa Roy J. and Lucille A. Carver College of Medicine, Iowa City, Iowa
5 Novartis Pharmaceuticals, East Hanover, New Jersey

View larger version (94K):
[in a new window]
|
FIGURE 1. Pretherapy (A) and posttherapy (B) CT images of liver of patient 7 show that multiple large, hypodense lesions seen at baseline were significantly smaller on posttherapy CT.
|
|

View larger version (89K):
[in a new window]
|
FIGURE 2. Pretherapy (A) and posttherapy (B) CT images of liver of patient 10 show that multiple large, hypodense lesions seen at baseline did not change significantly after therapy.
|
|
Copyright © 2003 by the Society of Nuclear Medicine.